The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Managed to buy another 50,000 at just under 16p just before 3pm
The reason I know they were buys is because they were both mine
Trying to buy significant amounts of shares at up to 16.1p today currently without success.
As the share price falls in the short term, the opportunity of picking up more shares presents itself providing the funds are available.
I am continuing to add to my holdings and will continue with holding my holdings over the very long term in my case.
Card Factory result today shows what can happen when you put up prices and people still buy your product.
They put up prices 12% on average and have reported profits up by nearly 400%
12 Noon
Two purchases of approx 48,000 shares were buys - I know because they were mine.
Genedrive mentioned in today's Investors Chronicle.
"Diagnostics moves beyond the Lab" written by Jennifer Johnson
David Budd quoted on AIHL and stroke aspects needing virtually immediate results at Point of Care to be of benefit to patients.
Twenty minutes before the market close yesterday 10% of the shares in the company changed hands. Marked as a sell but only 1p below the selling price at the time so my assumption is a very willing buyer on the other side.
Expect an RNS shortly
Just to be clear it is not permitted for a private individual to buy a Genedrive unit.
Top Ten
Calculus/Investec
Spreadex, Odey, Unicorn
MI Sterling, Octopus
4 Individual Investors
Although many of these are somewhat out of date ie say from 2020
According to Stockopedia Global Health Investment Fund have dropped out of the top ten shareholders and gone below 0.7 % at which the number 10 shareholder sits.
One thing to add
From the presentation slides I believe that the Company are working on a new piece of physical hardware [I am going to call it Genedrive 2] to replace the existing physical hardware Genedrive unit. This relates to the POC Point of Care setting.
Assuming I am right nobody is going to want Gendrive 1 if Genedrive 2 is shortly to become available. This may therefore be 'holding up' many things.
Ordinarily you would be able to attend the AGM and make a prior request to examine the full list of current shareholders. A request which ordinarily could not be denied.
Can buy 27,499 shares at 70p but no quote on Barclays for 27,501
Silence can be golden
Barclays will take a dummy sell of 29,000 shares at £1.3375 but draw the line at offering a price on a dummy sell of 30,000 shares.
Beckman Coulter unsurprisingly like to focus on themselves as the main event with Genedrive in a supporting role.
Beckman Coulter look to themselves to make the difference in their performance numbers, and they see the difference going forward coming primarily from a concentrated focus on their Biomek automation series.
All this bodes well for Genedrive in my opinion, although do not expect Genedrive going forward to get many headline mentions.
Headline mentions or not some of the good stuff will rub off on Genedrive as a direct result of Beckman Coulter's undoubted talent for self promotion.
Merger and Acquisition.
Listened to the webcast on Danaher.com - investors section. Main takeaways
Accelerating Cytiva's capacity, Cytiva transition going very well and exceeding expectations, Cytiva as high single digit growth business, labs increasing capacity, no softening of covid diagnostic testing, workflow ease is critical, testing in care setting as a focus, merger & acquisition focus is on small/medium sized deals, Danaher as cash flow machine, Danaher looking to deploy capital into M & A.
Make of this what you will.